OOIR: Observatory of International Research

Papers

(The median citation count of American Journal of Clinical Dermatology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease	124
Acknowledgment to Referees	121
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation	115
Chronic Telogen Effluvium: Is it a Distinct Condition? A Systematic Review	114
Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies	109
50 Years of Topical Retinoids for Acne: Evolution of Treatment	86
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination	85
Sunscreens and Photoaging: A Review of Current Literature	83
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis	80
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm	79
Tralokinumab for the Treatment of Atopic Dermatitis	75
Clinical Disease Measures in Generalized Pustular Psoriasis	73
Efinaconazole in Onychomycosis	67
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”	65
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety	59
Diagnosis of Generalized Pustular Psoriasis	58
Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study	54
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics	50
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma	49
Meat Allergy: A Ticking Time Bomb	49
Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments	48
Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments	44
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma	42
Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases	41
Economic Burden of Chronic Hand Eczema: A Review	40

Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	39
What’s New in Topicals for Atopic Dermatitis?	39
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists	39
Classification and Treatment of Angioedema without Wheals: A Spanish Delphi Consensus	38
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	37
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”	36
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	35
Dapsone Use in Dermatology	35
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program	35
The Potential Role of Cannabidiol in Cosmetic Dermatology: A Literature Review	35
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	34
Capturing the Diversity of Dermatology—What’s in a Name?	34
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada	31
Blue Nail Discoloration: Literature Review and Diagnostic Algorithms	31
Non-invasive Skin Imaging in Cutaneous Lymphomas	31
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance	31
Image-Based Artificial Intelligence in Psoriasis Assessment: The Beginning of a New Diagnostic Era?	30
Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”	29
Rare Autoinflammatory Neutrophilic Dermatoses in Pregnancy: Literature Review	29
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	29
Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview	29
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study	29
Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study	28
Individualized Neoantigen-Directed Melanoma Therapy	28
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis	28
Frontal Fibrosing Alopecia: An Update	28
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	28
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New?	26
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	25
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	25
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study	24
Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clini	24
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis	23
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data	23
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?	22
Therapeutic Strategies for Untreated Capillary Malformations of the Head and Neck Region: A Systematic Review and Meta-Analyses	22
The Use of Lasers and Light Devices in Acne Management: An Update	22
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice	21
Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020	21
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment	21
What’s New in Therapy for Male Androgenetic Alopecia?	20
Eyebrow and Eyelash Alopecia: A Clinical Review	20
Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis	20
Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions	20
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	20
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial	20
A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results	20
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial	20
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)	20
Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors	19

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments	18
Review of Teledermatology: Lessons Learned from the COVID-19 Pandemic	18
Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review	18
Pressure and Skin: A Review of Disease Entities Driven or Influenced by Mechanical Pressure	18
Alopecia Areata: Current Treatments and New Directions	18
Targeting Inflammation in Acne: Current Treatments and Future Prospects	18
Mucocutaneous Manifestations of Recreational Drug Use	18
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial	17
Correction to: Adherence to Hidradenitis Suppurativa Treatment	17
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials	17
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations	17
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”	16
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study	16
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History	16
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma	16
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	16
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target	16
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey	15
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	15
Teledermatology During COVID-19: An Updated Review	15
Photoprotection for Skin of Color	15
Primary Localized Cutaneous Amyloidosis of Keratinocyte Origin: An Update with Emphasis on Atypical Clinical Variants	15
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians	15
The Busy Arena of Psoriasis Treatments: Improving the Clinician’s Ability to Make the Right Therapeutic Choice	14
Investigational Treatments for Epidermolysis Bullosa	14
Early Treatment Initiation Improves Outcomes in Nevus of Ota: A 10-Year Retrospective Study	14
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review	14
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials	14
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program	14
The Role of Diet Modification in Atopic Dermatitis: Navigating the Complexity	14
Identifying and Treating Ocular Manifestations in Psoriasis	14
Leukonychia: What Can White Nails Tell Us?	14
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis	14
Pathophysiology of Generalized Pustular Psoriasis	13
Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study	13
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis	13
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database	12
Characteristics and Burdens of Disease in Patients from Beijing with Generalized Pustular Psoriasis and Palmoplantar Pustulosis: Multicenter Retrospective Cohort Study Using a Regional Database	12
Deucravacitinib for the Treatment of Psoriatic Disease	12
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management	12
Eosinophil–Lymphocyte Ratio, Eosinophil–Neutrophil Ratio, and Eosinophil–Monocyte Ratio in Chronic and Severe Urticaria	12
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis	12
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management	12
Muir–Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies	12
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update	11
Treat-to-Target in Atopic Dermatitis	11
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy	11
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study	11
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	11
Adherence to Hidradenitis Suppurativa Treatment	10
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year	10
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options	10
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	10
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors	10
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	10
Beyond the Hot Comb: Updates in Epidemiology, Pathogenesis, and Treatment of Central Centrifugal Cicatricial Alopecia from 2011 to 2021	10
Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009–2022)	10
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program	10
Author’s Reply to Parvathaneni et al. Comment on: “Methotrexate Cutaneous Ulceration: A Systematic Review of Cases”	10
Management of Acne in Pregnancy	9
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review	9
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients	9
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies	9
Approach to the Atypical Wound	9
Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review	9
From Compression to Itch: Exploring the Link Between Nerve Compression and Neuropathic Pruritus	9
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial	9
Managing the Patient with Psoriasis and Metabolic Comorbidities	9
Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient	8
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies	8
Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study	8
Behçet Disease: An Update for Dermatologists	8
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris	8
Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study	8
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study	7
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea	7
Acknowledgement to Referees	7
Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis	7
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program	7
Infections in Patients with Atopic Dermatitis and the Influence of Treatment	7

Acknowledgement to Referees	7
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	7
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma	6
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors	6
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure	6
Real-World Experience of Spesolimab for Generalized Pustular Psoriasis Flares in Adult Patients: A Multicenter Retrospective Study	6
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outco	6
Cellulitis: A Review of Current Practice Guidelines and Differentiation from Pseudocellulitis	6
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	6
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study	6
Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus	6
Overcoming Resistance Mechanisms to Melanoma Immunotherapy	6
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature	6
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Cl	6
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study	6
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program	6
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study	6